BioSpace News Archive

Quotient Limited, a commercial-stage diagnostics company, headquartered in Eysins, Switzerland, announced New York Blood Center, Inc., USA, and Centro de Transfusiones de la Comunidad de Madrid, Spain have joined MosaiQ’s Innovator’s Circle.

Moderna, Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines, announced a new supply agreement with the Swiss Federal Government for seven million doses of Moderna’s COVID-19 booster vaccine for anticipated delivery in 2023 and an additional option of seven million doses for delivery in 2023 and 2024.

bioLytical Laboratories Inc. announced that it is launching a new platform, iStatis, and has received its CE Mark for immediate market entry into Europe for its iStatis COVID-19 Antigen Home Test.

Atom Bioscience, a clinical stage biotechnology company developing new treatments for inflammatory and metabolic diseases, announced the results of a randomized double-blind, placebo-controlled Phase 2a clinical trial of ABP-671 to treat chronic gout.

Pardes Biosciences, Inc. today announced that it will give an oral presentation at the 35th International Conference On Antiviral Research (ICAR) 2022, to be held in Seattle and virtually from March 21-25 2022.

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced analysis results onTNX-102 SL.

Chimerix today announced that Mike Sherman, Chief Executive Officer, will present a pre-recorded presentation at the Maxim Group 2022 Virtual Growth Conference taking place March 28-30, 2022.

Recro Pharma, Inc. today announced that it is changing its name to Societal CDMO, Inc. to reflect the corporate transformation that has taken place primarily as a result of its acquisition and successful integration of IriSys, Inc. into the organization.

Provention Bio, Inc. today announced that the resubmitted Biologics License Application (BLA) for teplizumab for the delay of clinical type 1 diabetes (T1D) in at-risk individuals has been considered a complete, class 2 response to the July 2021 action letter by the U.S. Food and Drug Administration (FDA).

EVUSHELD ™ long-acting antibody combination retains neutralizing activity against Omicron variants including BA.2 in new independent studies.